Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.

doi:10.1128/JCM.39.6.2206-2212.2001

Article

Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.

Journal of clinical microbiology - 1 Jun 2001

Paterson D L, Ko W C, Von Gottberg A, Casellas J M, Mulazimoglu L, Klugman K P, Bonomo R A, Rice L B, McCormack J G, Yu V L

Abstract excerpt

Although extended-spectrum beta-lactamases (ESBLs) hydrolyze cephalosporin antibiotics, some ESBL-producing organisms are not resistant to all cephalosporins when tested in vitro. Some authors have suggested that screening klebsiellae or Escherichia coli for ESBL production is not clinically necessary, and when most recently surveyed the majority of American clinical microbiology laboratories did not make efforts...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.

Abstract excerpt

Topics

Related research